Clinical Laserthermia Systems AB
23 Aug - 6 Sep 2022Rights issue
At CLS, they aim at getting doctors as close as possible to the clinical problem and provide the means needed for solving it – without causing another. They do this by providing precise tools for image-guided laser-mediated thermal ablations.
Thermal ablation is used for treatment and removal of diseased or abnormal soft tissues, such as malignant tumors (cancer) or epileptogenic foci. The procedure is minimally invasive and can therefore be offered also to patients that are considered inoperable in view of traditional open surgery.
The offer in summary
Record date: 18 August 2022
Subscription period: 23 August - 6 September 2022
Subscription rights: Anyone who were shareholder in the Company on the record date of August 18, 2022 has a preferential right to subscribe for units in the rights issue in relation to previous holdings, whereby one (1) existing share gives one (1) unit rights. Two (2) unit rights entitle to subscribe for one (1) new unit. One (1) unit consists of two (2) new B-shares and one (1) warrant of series TO 5.
Subscription price: 2.00 SEK per unit
The offer: 34 653 275 units which corresponds to ca 69 MSEK
Trading with unit rights: 23 August - 1 September 2022
Marketplace: Nasdaq First North Growth Market
Financial advisor: Sedermera Corporate Finance
Subscribe directly at Avanza here
Subscribe directly at Nordnet here